New stock news | Fosun Antaeus filed with Hong Kong Stock Exchange
According to the Hong Kong Stock Exchange on June 26, Fosun Pharma (Chengdu) Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and Fosun International Capital as its joint sponsors.
According to the Hong Kong Stock Exchange disclosure on June 26, Fosun Pharma (Chengdu) Biopharmaceutical Co., Ltd. (referred to as "Fosun Pharma") has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with CICC and Fosun Intl Capital acting as joint sponsors. The prospectus shows that Fosun Pharma is a vaccine company with the capabilities of vaccine research, production, and commercialization. The company has built a diversified and multi-level product pipeline, focusing on areas of significant commercial value such as pneumonia, meningitis, rabies, and influenza. It operates research and production bases in Chengdu and Dalian.
Related Articles
ASIAPAC FIN INV (08193) released its annual performance results, with shareholders' share of profit amounting to 36.609 million Hong Kong dollars, turning a loss into a profit year-on-year.
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) rose more than 4%, with the amount of stock repurchase exceeding 1.99 billion RMB so far this year.
AI computing power demand continues to be hot! Amazon.com, Inc. (AMZN.US) Cloud computing business AWS once again raised GPU capacity reservation service prices.
ASIAPAC FIN INV (08193) released its annual performance results, with shareholders' share of profit amounting to 36.609 million Hong Kong dollars, turning a loss into a profit year-on-year.
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) rose more than 4%, with the amount of stock repurchase exceeding 1.99 billion RMB so far this year.
AI computing power demand continues to be hot! Amazon.com, Inc. (AMZN.US) Cloud computing business AWS once again raised GPU capacity reservation service prices.
RECOMMEND
